Growth hormone for optimization of refractory heart failure treatment

Arquivos Brasileiros de Cardiologia

Volumn 73, Issue 4, 1999, Pages 395-398

  Bocchi, Edimar Alcides ^a   Massuda, Zyun ^a   Guimarães, Guilherme ^a   Carrara, Dirceu ^a   Bellotti, Giovanni ^a   Mocelin, Amilcar ^a   Sobrinho, Carlos Roberta Martins Rodrigues ^a   Ramires, José Franchini ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMILORIDE PLUS HYDROCHLOROTHIAZIDE; CAPTOPRIL; CARVEDILOL; DIGOXIN; DOBUTAMINE; FUROSEMIDE; GROWTH HORMONE; SOMATOMEDIN C;

ADULT; ARTICLE; CACHEXIA; CASE REPORT; CONGESTIVE HEART FAILURE; EXERCISE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART TRANSPLANTATION; HORMONE SUBSTITUTION; HUMAN; LUNG PRESSURE; MALE;

CACHEXIA; HEART FAILURE, CONGESTIVE; HUMAN GROWTH HORMONE; HUMANS; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 0039841906     PISSN: 0066782X     EISSN: None     Source Type: Journal    
DOI: 10.1590/S0066-782X1999001000007     Document Type: Article

References (35)

1. Bocchi EA, Bellotti G, Moreira LF, et al. Mid-terms result of heart transplantation, cardiomyoplasty, and medical treatment of refratory heart failure caused by idiopathic dilated cardiomyopathy. J Heart Lung Transplant 1996; 15: 736-45.
2. Bocchi EA, Bacal F, Bellotti G, Carrara D, Ranmires JAF. Efeitos do carvedilol (bloqueador b1b2a1) na insuficiência cardíaca refratária. Arq Bras Cardiol 1998; 78: 169-73.
3. Bocchi EA, Bellotti G, Moraes AV, et al. Clinical outcome after left ventricular surgical remodeling in patients with idiopathic dilated cardiomyoapathy reeferred for heart transplantation. Short-term results. Circulation 1997; 96: II-165-II-72.
4. Bocchi EA, Higuchi ML, Vieira MC, et al. Higher incidence of malignant neoplasms after heart transplantation for treatment of chronic Chagas' heart disease. J Heart Transplant 1998; 17: 399-405.
5. Lommi J, Koskiner P, Naveri H, Harkonen M, Kupari M. Heart failure ketosis. I Intern Med 1997; 242: 231-8.
6. Niebauer J, Pflaum C-D, Clark AL, et al. Deficient insulin-like growth factor in chronic heart failure predicts altered composition, anabolic deficiency, cytokine and neurohormonal activation. J Am Coll Cardiol 1998; 32: 393-7.
7. Anker SD, Chua TP, Ponikowski P, et al. Hormonal changes and catabalic/anabolic imbalance i chronic heart failure and their importance in cardiac cachexia. Circulation 1997; 96: 526-34.
8. Anand IA, Ferrari R, Kalra GS, Wahi PL, Poole-Wilson PA, Harris PC. Edema of cardiac origin: studies of body water and sodium, renal function, hemodynamic indexes, and plasma hormones in untreated congestive heart failure. Circulation 1989; 80: 299-305.
9. Fazio S, Cittadini A, Merola B, et al. Growth hormone and heart peformance. A novel mechanism of cardiac wall stress regulation in humans. Eur Heart J 1997; 18: 340-7.
10. Gomberg-Maitland M, Frishman WH. Recombinant growth hormone: a new cardiovascular drug therapy. Am Heart J 1996; 132: 1244-62.
11. Giustina A, Lorusso R, Borghetti V, Bugari G, Misitano V, Alfieri O. Impaired spontaneous growth hormone secretion in severe dilated cardiomyopathy. Am Heart J 1996; 131: 620-22.
12. Anker SD, Chua TP, Ponikowski P, et al. Hormonal changes and catabolic/ianabolic imbalance in chronic heart failure and their importance in cardiac caquexia. Circulation 1997; 96: 526-34.
13. Yang R, Bunting S, Gillett N, Clark R, Jin H. Growth hormone improves cardiac performance in experimental heart failure. Circulation 1995; 92: 262-7.
14. Duerr RL, McKirnan D, Gim RD, Clark RG, Chien KR, Ross J. Cardiovascular effects of insulin-like growth factor-1 and growth hormone in chronic left ventricular failure in the rat. Circulation 1996; 93: 2188-96.
15. Shen YT, Woltmann RF, Appleby S, et al. Lack of beneficial effects of growth hormone treatment in conscious dogs during development of heart failure. Am J Physiol 1998; 242: H456-66.
16. Casragnino HE, Toranzos FA, Milei J, et al. Preservation of the myocardial collagen framework by human growth hormone in experiemental infarctions and reduction in the incidence ventricular aneurysms. Int J Cardiol 1992; 35: 101-14.
17. Frustad A, Pesone GA, Gentiloni N, Russo MA. Reversible dilated cardiomyopathy due to growth hormone deficiency. Am J Clin Pathol 1992; 97: 503-11.
18. Fazio S, Sabatini D, Capaldo B, et al. A preliminary study of growth hormone in the treatment of dilated cardiomyopathy. N Engl J Med 1996; 334: 809-14.
19. Cuneo RC, Wilmshurst P, Lowy C, Mcgauley G, Sonsksen PH. Cardiac failure responding to growth hormone. Lancet 1989; 1: 838-9.
20. Volterrani M, Desenzani P, Lorusso R, Manelli F, Giustina A. Hemodynamic effects of intravenous growth hormone in congestive heart failure. Lancet 1997; 349: 1067-8.
21. Driscoll JGO, Green DJ, Ireland M, Kerr D, Larbalestier RI. Treatment of end-stage cardiac failure with growth hormone. Lancet 1997; 349: 1068.
22. Osterziel KJ, Strohm O, Schuler J, el al. Randomised, double-blind, placebo-controlled trial of human recombinant growth hormone in patients with chronic heart failure due to dilated cardiomyopathy. Lancet 1998; 351: 1233-7.
23. Monson JP, Besser GM. The potential for growth hormone in the management of heart failure. Heart 1997; 771-2.
24. Ross J, Hongo M. The role of hypertrophy and growth factors in heart failure. J Card Fail 1996; 4: S121-8.
25. Pulkki K. Cytokines and cardiomyopathy death. Ann Med 1997; 29: 339-43.
26. Capaldo B, Lembo G, Rendina V, et al. Sympathetic deactivation by growth hormone treatment in patients with dilated cardiomyopathy. Eur Heart J 1998; 19: 623-7.
27. Silverman BL, Friedlander JR. Is growth hormone good for the heart? J Pediatr 1997; 131: S70-4.
28. Colao A, Lombardi G. Growth-hormone and prolactin excess. Lancet 1998; 353: 1455-61.
29. Prager D, Li HL, Asa S, Melmed S. Dominant negative inhibition of tumorgenesis in vivo by insulin-like growth factor-1 receptor mutant. Proc Natl Acad Sci 1994; 91: 2181-5.
30. Kalebic T, Tsokos M, Helman LJ. In vivo treatment with antibody against the IGF-I eceptor suppresses growth of human rhabdomyosarcoma and down-regulates p34/cd2. Cancer Res 1994; 54: 5531-4.
31. Arteaga CL, Osborne CK. Growth inhibition of human breast cancer cells in vitro with an antibody against the type 1 somato medin receptor. Cancer Res 1989; 49: 6237-41.
32. Resnicoff M, Burgaud JL, Rotman HL, Abraham D, Baserga R. Correlation between apoptosis, tumorigenesis, and levels of insulin-factor 1 receptors. Cancer Res 1995; 55: 3739-41.
33. Resnicoff M, Abraham D, Yutanawiboonchai W, et al. The insulin-like growth factor receptor protects tumor cells from apoptosis in vivo. Cancer Res 1995; 55: 2463-9.
34. Kaleko M, Rutter WG, Miller AD. Overexpression of the human insulin-like growth factor 1 receptor promoters ligand-dependent neoplastics transformation. Mol Cell Biol 1990; 10: 464-73.
35. Ho KY, Kelly JJ. Role of growth hormone in fluid homeostasis. Horm Res 1991; 36(suppl 1): 44-8.